|
![]() |
|
|
Indocin: profile and news
LOSS OF BOWEL CONTROL IS OFTEN TREATABLE Mar 1, 2006 Loss of bowel control is distressing, but treatable Mar 1, 2006 SSRIs harm baby's breath? Feb 24, 2006 KEN RUCKER SUSPENDED Dec 10, 2005 Crime Reports Dec 1, 2005 STOPPING MEDICINE WITHOUT TELLING THE DOCTOR IS DANGEROUS Nov 30, 2005 Brown Can Look and Learn Nov 20, 2005 Notebook: Brown has hamstring injury Nov 21, 2005 Hand-washing no shield against spread of germs Oct 27, 2005 Popular pain medications: Help or harm? Rx ANSWERS WILKES ... Oct 11, 2005 Popular pain medications: Help or harm? Rx ANSWERS WILKES ... 11 Oct 2005 What Ails You by Jackie Randa Sep 20, 2005 Even if you wash hands, restroom germs still lurk Sep 19, 2005 The Medical Minute: Pain - the fifth vital sign Aug 31, 2005 Guam's bout with gout 06 Aug 2005 Ask Dr. Husty: Aspirin Alternative During Heart Attack? Jun 20, 2005 Most Painkillers Up Heart Attack Risk Jun 17, 2005 Ask Dr. Husty: Aspirin Alternative During Heart Attack? Jun 20, 2005 Most Painkillers Up Heart Attack Risk Jun 17, 2005 CONFERENCE REPORT: Less Cancer With NSAIDs But More Cardiovascular ... Apr 18, 2005 Sarcoidosis isn'ta laughing matter Apr 14, 2005 FDA pulls painkiller Bextra, orders new warnings Apr 8, 2005 Another painkiller, Bextra, ordered pulled Apr 8, 2005 Painkiller Bextra pulled from shelves Apr 8, 2005 Worry over drug safety adds to patients’ pain Mar 6, 2005 Is a new culture pending for Food & Drug Administration? Feb 26, 2005 Old proverb about gout does not apply Feb 11, 2005 FDA Panel Says Celebrex Should Stay on Market Feb 18, 2005 FDA Scientist Says All Cox-2 Drugs Pose a Risk Feb 18, 2005 FDA scientist sees problems with entire class of painkillers Feb 18, 2005 Merck executive raises the possibility of Vioxx's return Feb 18, 2005 FDA Panel Urges Caution on Many Anti-Inflammatory Drugs Feb 24, 2005 Hearings show more openness by FDA on drugs Feb 20, 2005 Other information Indication For moderate to severe rheumatoid arthritis including acute flares of chronic disease, ankylosing spondylitis, osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis. Pharmacology Indomethacin, a nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain. Mechanism Of Action Antiinflammatory effects of Indomethacin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Drug Category Tocolytic Agents; Cardiovascular Agents; Anti-inflammatory Agents; Nonsteroidal Antiinflammatory Agents (NSAIDs); ATC:S01BC; ATC:M01AB Brand Names/Synonyms Amuno; Apo-Indomethacin; Argun; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Bonidon Gel; CCRIS 3502; Catlep; Chibro-Amuno; Chrono-Indicid; Chrono-Indocid; Confortid; Dolcidium; Dolcidium Pl; Dolovin; Durametacin; Elmetacin; Flexin Continus; HSDB 3101; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indo-Lemmon; Indo-Phlogont; Indo-Rectolmin; Indo-Spray; Indo-Tablinen; Indocid; Indocid Pda; Indocid Sr; Indocin; Indocin I.V; Indocin I.V.; Indocin Sr; Indolar Sr; Indomecol; Indomed; Indomee; Indometacin; Indometacine; Indometacyna; Indomethacin; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Inteban Sp; Lausit; Liometacen [As Meglumine Salt]; Metacen; Metartril; Methazine; Metindol; Mezlin; Mezlocillin; Mezolin; Miametan; Mikametan; Mobilan; Novo-Methacin; Novomethacin; Nu-Indo; Reumacide; Rhemacin La; Rheumacin La; Sadoreum; Tannex; USAN; Vonum Dosage Forms CAPSULE Absorption Not Available Interactions Interactions for Indomethacin: In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin. In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage. Therefore, diflunisal and INDOCIN should not be used concomitantly. In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%. The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy. Clinical studies have shown that INDOCIN does not influence the hypoprothrombinemia produced by anticoagulants. However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time. In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN. Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly. When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased. Therefore, a lower total daily dosage of INDOCIN may produce a satisfactory therapeutic effect. When increases in the dose of INDOCIN are made, they should be made carefully and in small increments. Caution should be used if INDOCIN is administered simultaneously with methotrexate. INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity. Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin. NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored. Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations. This effect has been attributed to inhibition of prostaglandin synthesis. As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity. (Read circulars for lithium preparations before use of such concomitant therapy.) In addition, the frequency of monitoring serum lithium concentration should be increased at the outset of such combination drug treatment. INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored. In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics. Therefore, when INDOCIN and INDOCIN. (Indomethacin) diuretics are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained. INDOCIN reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or volume depletion. These facts should be considered when evaluating plasma renin activity in hypertensive patients. It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers. INDOCIN and triamterene should not be administered together. INDOCIN and potassium-sparing diuretics each may be associated with increased serum potassium levels. The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently. Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN. Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported. Therefore, when using these blocking agents to treat hypertension, patients should be observed carefully in order to confirm that the desired therapeutic effect has been obtained. INDOCIN can reduce the antihypertensive effects of captopril and losartan. False-negative results in the dexamethasone suppression test (DST) in patients being treated with INDOCIN have been reported. Thus, results of the DST should be interpreted with caution in these patients. Chemical IUPAC Name 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]ethanoicacid Chemical Formula C19H16ClNO4 Half Life 4.5 hours Drug Type Approved Drug # Accession No APRD00109 CAS Registry Number 53-86-1 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |